[Efficacy of anti-neuraminidase drugs application during and after an influenza pandemic].
Identifieur interne : 001F35 ( PubMed/Checkpoint ); précédent : 001F34; suivant : 001F36[Efficacy of anti-neuraminidase drugs application during and after an influenza pandemic].
Auteurs : N V Breslav ; E S Shevchenko ; D D Abramov ; A G Prilipov ; M M Zhuravleva ; T A Oskerko ; L V Kolobukhina ; L N Merkulova ; M Iu Shchelkanov ; E I Burtseva ; D K L'VovSource :
- Voprosy virusologii [ 0507-4088 ]
Descripteurs français
- KwdFr :
- Animaux, Antienzymes (administration et posologie), Chiens, Femelle, Grippe humaine (enzymologie), Grippe humaine (génétique), Grippe humaine (épidémiologie), Humains, Lignée cellulaire, Mâle, Oséltamivir (administration et posologie), Pandémies, Russie, Résistance virale aux médicaments (), Résistance virale aux médicaments (génétique), Sialidase (antagonistes et inhibiteurs), Sialidase (génétique), Sous-type H1N1 du virus de la grippe A (enzymologie), Sous-type H1N1 du virus de la grippe A (génétique), Études rétrospectives.
- MESH :
- administration et posologie : Antienzymes, Oséltamivir.
- antagonistes et inhibiteurs : Sialidase.
- enzymologie : Grippe humaine, Sous-type H1N1 du virus de la grippe A.
- génétique : Grippe humaine, Résistance virale aux médicaments, Sialidase, Sous-type H1N1 du virus de la grippe A.
- épidémiologie : Grippe humaine.
- Animaux, Chiens, Femelle, Humains, Lignée cellulaire, Mâle, Pandémies, Russie, Résistance virale aux médicaments, Études rétrospectives.
English descriptors
- KwdEn :
- Animals, Cell Line, Dogs, Drug Resistance, Viral (drug effects), Drug Resistance, Viral (genetics), Enzyme Inhibitors (administration & dosage), Female, Humans, Influenza A Virus, H1N1 Subtype (enzymology), Influenza A Virus, H1N1 Subtype (genetics), Influenza, Human (enzymology), Influenza, Human (epidemiology), Influenza, Human (genetics), Male, Neuraminidase (antagonists & inhibitors), Neuraminidase (genetics), Oseltamivir (administration & dosage), Pandemics, Retrospective Studies, Russia.
- MESH :
- chemical , administration & dosage : Enzyme Inhibitors, Oseltamivir.
- chemical , antagonists & inhibitors : Neuraminidase.
- geographic : Russia.
- drug effects : Drug Resistance, Viral.
- enzymology : Influenza A Virus, H1N1 Subtype, Influenza, Human.
- epidemiology : Influenza, Human.
- genetics : Drug Resistance, Viral, Influenza A Virus, H1N1 Subtype, Influenza, Human, Neuraminidase.
- Animals, Cell Line, Dogs, Female, Humans, Male, Pandemics, Retrospective Studies.
Abstract
The emergent 2009 A(H1N1) pandemic brought into acute focus the problem of choosing the most effective anti-influenza drugs for successive influenza infection spreading control. Oseltamivir and zanamivir, influenza virus neuraminidase inhibitors (NAIs), were recommended by the WHO experts for the treatment and prevention of influenza, including that caused by pandemic strains. A major concern regarding the use of specific antiviral compounds is the emergence of the drug-resistant strains. Oseltamivir carboxylate and zanamivir IC50 values were equal to 0.3-5.2 microM for the most of A(H1N1)pdm09 pandemic strains and 1.6-8.6 microM for the strains of influenza B virus in cell-based ELISA assay (2009-2010 season). All the studied strains of influenza A(H1N1 ) pdm09 (151) and B (22) viruses were sensitive to NAIs (2009-2011 seasons). For the first time in Russia oseltamivir-resistant A(H1N1) pdm09 influenza virus was isolated from the patient on the 5th day of a treatment course of this drug.
PubMed: 23785758
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:23785758Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Efficacy of anti-neuraminidase drugs application during and after an influenza pandemic].</title><author><name sortKey="Breslav, N V" sort="Breslav, N V" uniqKey="Breslav N" first="N V" last="Breslav">N V Breslav</name></author><author><name sortKey="Shevchenko, E S" sort="Shevchenko, E S" uniqKey="Shevchenko E" first="E S" last="Shevchenko">E S Shevchenko</name></author><author><name sortKey="Abramov, D D" sort="Abramov, D D" uniqKey="Abramov D" first="D D" last="Abramov">D D Abramov</name></author><author><name sortKey="Prilipov, A G" sort="Prilipov, A G" uniqKey="Prilipov A" first="A G" last="Prilipov">A G Prilipov</name></author><author><name sortKey="Zhuravleva, M M" sort="Zhuravleva, M M" uniqKey="Zhuravleva M" first="M M" last="Zhuravleva">M M Zhuravleva</name></author><author><name sortKey="Oskerko, T A" sort="Oskerko, T A" uniqKey="Oskerko T" first="T A" last="Oskerko">T A Oskerko</name></author><author><name sortKey="Kolobukhina, L V" sort="Kolobukhina, L V" uniqKey="Kolobukhina L" first="L V" last="Kolobukhina">L V Kolobukhina</name></author><author><name sortKey="Merkulova, L N" sort="Merkulova, L N" uniqKey="Merkulova L" first="L N" last="Merkulova">L N Merkulova</name></author><author><name sortKey="Shchelkanov, M Iu" sort="Shchelkanov, M Iu" uniqKey="Shchelkanov M" first="M Iu" last="Shchelkanov">M Iu Shchelkanov</name></author><author><name sortKey="Burtseva, E I" sort="Burtseva, E I" uniqKey="Burtseva E" first="E I" last="Burtseva">E I Burtseva</name></author><author><name sortKey="L Vov, D K" sort="L Vov, D K" uniqKey="L Vov D" first="D K" last="L'Vov">D K L'Vov</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="????"><PubDate><MedlineDate>2013 Jan-Feb</MedlineDate></PubDate></date><idno type="RBID">pubmed:23785758</idno><idno type="pmid">23785758</idno><idno type="wicri:Area/PubMed/Corpus">000A03</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A03</idno><idno type="wicri:Area/PubMed/Curation">000A03</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000A03</idno><idno type="wicri:Area/PubMed/Checkpoint">001F35</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001F35</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Efficacy of anti-neuraminidase drugs application during and after an influenza pandemic].</title><author><name sortKey="Breslav, N V" sort="Breslav, N V" uniqKey="Breslav N" first="N V" last="Breslav">N V Breslav</name></author><author><name sortKey="Shevchenko, E S" sort="Shevchenko, E S" uniqKey="Shevchenko E" first="E S" last="Shevchenko">E S Shevchenko</name></author><author><name sortKey="Abramov, D D" sort="Abramov, D D" uniqKey="Abramov D" first="D D" last="Abramov">D D Abramov</name></author><author><name sortKey="Prilipov, A G" sort="Prilipov, A G" uniqKey="Prilipov A" first="A G" last="Prilipov">A G Prilipov</name></author><author><name sortKey="Zhuravleva, M M" sort="Zhuravleva, M M" uniqKey="Zhuravleva M" first="M M" last="Zhuravleva">M M Zhuravleva</name></author><author><name sortKey="Oskerko, T A" sort="Oskerko, T A" uniqKey="Oskerko T" first="T A" last="Oskerko">T A Oskerko</name></author><author><name sortKey="Kolobukhina, L V" sort="Kolobukhina, L V" uniqKey="Kolobukhina L" first="L V" last="Kolobukhina">L V Kolobukhina</name></author><author><name sortKey="Merkulova, L N" sort="Merkulova, L N" uniqKey="Merkulova L" first="L N" last="Merkulova">L N Merkulova</name></author><author><name sortKey="Shchelkanov, M Iu" sort="Shchelkanov, M Iu" uniqKey="Shchelkanov M" first="M Iu" last="Shchelkanov">M Iu Shchelkanov</name></author><author><name sortKey="Burtseva, E I" sort="Burtseva, E I" uniqKey="Burtseva E" first="E I" last="Burtseva">E I Burtseva</name></author><author><name sortKey="L Vov, D K" sort="L Vov, D K" uniqKey="L Vov D" first="D K" last="L'Vov">D K L'Vov</name></author></analytic><series><title level="j">Voprosy virusologii</title><idno type="ISSN">0507-4088</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Cell Line</term><term>Dogs</term><term>Drug Resistance, Viral (drug effects)</term><term>Drug Resistance, Viral (genetics)</term><term>Enzyme Inhibitors (administration & dosage)</term><term>Female</term><term>Humans</term><term>Influenza A Virus, H1N1 Subtype (enzymology)</term><term>Influenza A Virus, H1N1 Subtype (genetics)</term><term>Influenza, Human (enzymology)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (genetics)</term><term>Male</term><term>Neuraminidase (antagonists & inhibitors)</term><term>Neuraminidase (genetics)</term><term>Oseltamivir (administration & dosage)</term><term>Pandemics</term><term>Retrospective Studies</term><term>Russia</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Antienzymes (administration et posologie)</term><term>Chiens</term><term>Femelle</term><term>Grippe humaine (enzymologie)</term><term>Grippe humaine (génétique)</term><term>Grippe humaine (épidémiologie)</term><term>Humains</term><term>Lignée cellulaire</term><term>Mâle</term><term>Oséltamivir (administration et posologie)</term><term>Pandémies</term><term>Russie</term><term>Résistance virale aux médicaments ()</term><term>Résistance virale aux médicaments (génétique)</term><term>Sialidase (antagonistes et inhibiteurs)</term><term>Sialidase (génétique)</term><term>Sous-type H1N1 du virus de la grippe A (enzymologie)</term><term>Sous-type H1N1 du virus de la grippe A (génétique)</term><term>Études rétrospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Enzyme Inhibitors</term><term>Oseltamivir</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Neuraminidase</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Russia</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antienzymes</term><term>Oséltamivir</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Sialidase</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Drug Resistance, Viral</term></keywords><keywords scheme="MESH" qualifier="enzymologie" xml:lang="fr"><term>Grippe humaine</term><term>Sous-type H1N1 du virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Drug Resistance, Viral</term><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza, Human</term><term>Neuraminidase</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Grippe humaine</term><term>Résistance virale aux médicaments</term><term>Sialidase</term><term>Sous-type H1N1 du virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cell Line</term><term>Dogs</term><term>Female</term><term>Humans</term><term>Male</term><term>Pandemics</term><term>Retrospective Studies</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Chiens</term><term>Femelle</term><term>Humains</term><term>Lignée cellulaire</term><term>Mâle</term><term>Pandémies</term><term>Russie</term><term>Résistance virale aux médicaments</term><term>Études rétrospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The emergent 2009 A(H1N1) pandemic brought into acute focus the problem of choosing the most effective anti-influenza drugs for successive influenza infection spreading control. Oseltamivir and zanamivir, influenza virus neuraminidase inhibitors (NAIs), were recommended by the WHO experts for the treatment and prevention of influenza, including that caused by pandemic strains. A major concern regarding the use of specific antiviral compounds is the emergence of the drug-resistant strains. Oseltamivir carboxylate and zanamivir IC50 values were equal to 0.3-5.2 microM for the most of A(H1N1)pdm09 pandemic strains and 1.6-8.6 microM for the strains of influenza B virus in cell-based ELISA assay (2009-2010 season). All the studied strains of influenza A(H1N1 ) pdm09 (151) and B (22) viruses were sensitive to NAIs (2009-2011 seasons). For the first time in Russia oseltamivir-resistant A(H1N1) pdm09 influenza virus was isolated from the patient on the 5th day of a treatment course of this drug.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23785758</PMID><DateCompleted><Year>2013</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0507-4088</ISSN><JournalIssue CitedMedium="Print"><Volume>58</Volume><Issue>1</Issue><PubDate><MedlineDate>2013 Jan-Feb</MedlineDate></PubDate></JournalIssue><Title>Voprosy virusologii</Title><ISOAbbreviation>Vopr. Virusol.</ISOAbbreviation></Journal><ArticleTitle>[Efficacy of anti-neuraminidase drugs application during and after an influenza pandemic].</ArticleTitle><Pagination><MedlinePgn>28-32</MedlinePgn></Pagination><Abstract><AbstractText>The emergent 2009 A(H1N1) pandemic brought into acute focus the problem of choosing the most effective anti-influenza drugs for successive influenza infection spreading control. Oseltamivir and zanamivir, influenza virus neuraminidase inhibitors (NAIs), were recommended by the WHO experts for the treatment and prevention of influenza, including that caused by pandemic strains. A major concern regarding the use of specific antiviral compounds is the emergence of the drug-resistant strains. Oseltamivir carboxylate and zanamivir IC50 values were equal to 0.3-5.2 microM for the most of A(H1N1)pdm09 pandemic strains and 1.6-8.6 microM for the strains of influenza B virus in cell-based ELISA assay (2009-2010 season). All the studied strains of influenza A(H1N1 ) pdm09 (151) and B (22) viruses were sensitive to NAIs (2009-2011 seasons). For the first time in Russia oseltamivir-resistant A(H1N1) pdm09 influenza virus was isolated from the patient on the 5th day of a treatment course of this drug.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Breslav</LastName><ForeName>N V</ForeName><Initials>NV</Initials></Author><Author ValidYN="Y"><LastName>Shevchenko</LastName><ForeName>E S</ForeName><Initials>ES</Initials></Author><Author ValidYN="Y"><LastName>Abramov</LastName><ForeName>D D</ForeName><Initials>DD</Initials></Author><Author ValidYN="Y"><LastName>Prilipov</LastName><ForeName>A G</ForeName><Initials>AG</Initials></Author><Author ValidYN="Y"><LastName>Zhuravleva</LastName><ForeName>M M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Oskerko</LastName><ForeName>T A</ForeName><Initials>TA</Initials></Author><Author ValidYN="Y"><LastName>Kolobukhina</LastName><ForeName>L V</ForeName><Initials>LV</Initials></Author><Author ValidYN="Y"><LastName>Merkulova</LastName><ForeName>L N</ForeName><Initials>LN</Initials></Author><Author ValidYN="Y"><LastName>Shchelkanov</LastName><ForeName>M Iu</ForeName><Initials>MIu</Initials></Author><Author ValidYN="Y"><LastName>Burtseva</LastName><ForeName>E I</ForeName><Initials>EI</Initials></Author><Author ValidYN="Y"><LastName>L'vov</LastName><ForeName>D K</ForeName><Initials>DK</Initials></Author></AuthorList><Language>rus</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Russia (Federation)</Country><MedlineTA>Vopr Virusol</MedlineTA><NlmUniqueID>0417337</NlmUniqueID><ISSNLinking>0507-4088</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>20O93L6F9H</RegistryNumber><NameOfSubstance UI="D053139">Oseltamivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber><NameOfSubstance UI="D009439">Neuraminidase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024882" MajorTopicYN="Y">Drug Resistance, Viral</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="Y">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009439" MajorTopicYN="Y">Neuraminidase</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053139" MajorTopicYN="N">Oseltamivir</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012426" MajorTopicYN="N" Type="Geographic">Russia</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23785758</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list></list><tree><noCountry><name sortKey="Abramov, D D" sort="Abramov, D D" uniqKey="Abramov D" first="D D" last="Abramov">D D Abramov</name><name sortKey="Breslav, N V" sort="Breslav, N V" uniqKey="Breslav N" first="N V" last="Breslav">N V Breslav</name><name sortKey="Burtseva, E I" sort="Burtseva, E I" uniqKey="Burtseva E" first="E I" last="Burtseva">E I Burtseva</name><name sortKey="Kolobukhina, L V" sort="Kolobukhina, L V" uniqKey="Kolobukhina L" first="L V" last="Kolobukhina">L V Kolobukhina</name><name sortKey="L Vov, D K" sort="L Vov, D K" uniqKey="L Vov D" first="D K" last="L'Vov">D K L'Vov</name><name sortKey="Merkulova, L N" sort="Merkulova, L N" uniqKey="Merkulova L" first="L N" last="Merkulova">L N Merkulova</name><name sortKey="Oskerko, T A" sort="Oskerko, T A" uniqKey="Oskerko T" first="T A" last="Oskerko">T A Oskerko</name><name sortKey="Prilipov, A G" sort="Prilipov, A G" uniqKey="Prilipov A" first="A G" last="Prilipov">A G Prilipov</name><name sortKey="Shchelkanov, M Iu" sort="Shchelkanov, M Iu" uniqKey="Shchelkanov M" first="M Iu" last="Shchelkanov">M Iu Shchelkanov</name><name sortKey="Shevchenko, E S" sort="Shevchenko, E S" uniqKey="Shevchenko E" first="E S" last="Shevchenko">E S Shevchenko</name><name sortKey="Zhuravleva, M M" sort="Zhuravleva, M M" uniqKey="Zhuravleva M" first="M M" last="Zhuravleva">M M Zhuravleva</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F35 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001F35 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:23785758
|texte= [Efficacy of anti-neuraminidase drugs application during and after an influenza pandemic].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:23785758" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |